Related Experiment Video
Updated: May 26, 2026

Assessment of Knee Hyperalgesia in Mice using Pressure Application Measurement
Published on: June 13, 2025
The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory
Fred K C Chan1, Stephen S M Chung, Irene O Ng
1Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.
Abstract:
Deleted in liver cancer 2 (DLC2) is a novel Rho GTPase-activating protein that regulates RhoA activity. DLC2 is ubiquitously expressed in most tissues, including the brain, spinal cord and peripheral nerves, and is thought to be involved in actin cytoskeletal reorganization. Unlike DLC1-deficient mice, DLC2-deficient mice (DLC2(-/-)) are viable and without gross anatomical abnormalities. Interestingly, DLC2(-/-) mice exhibit hyperalgesia to noxious thermal stimuli and inflammation-inducing chemicals, such as formalin and acetic acid. There was no difference in the structure or morphology of cutaneous or sural nerves between DLC2(+/+) and DLC2(-/-) mice. However, sensory nerve conduction velocity in DLC2(-/-) mice was significantly higher than that in DLC2(+/+) mice, whereas motor nerve conduction velocity was not affected. After formalin injection, DLC2(-/-) mice showed increased RhoA activity in the spinal cord and an increased number of phosphorylated ERK1/2-positive cells. The inflammatory hyperalgesia in DLC2(-/-) mice appeared to be mediated through the activation of RhoA and ERK1/2. Taken together, DLC2 plays a key role in pain modulation during inflammation by suppressing the activation of RhoA and ERK to prevent an exaggerated pain response, and DLC2(-/-) mice provide a valuable tool for further understanding the regulation of inflammatory pain.
Insights
Deleted in liver cancer 2 (DLC2) deficiency in mice leads to heightened pain sensitivity and nerve signaling changes. This suggests DLC2 is crucial for regulating inflammatory pain responses.
Area of Science:
- Neuroscience
- Molecular Biology
- Pain Research
Background:
- Deleted in liver cancer 2 (DLC2) is a Rho GTPase-activating protein regulating RhoA.
- DLC2 is widely expressed, including in the nervous system, and influences the actin cytoskeleton.
- DLC2-deficient mice are viable but display altered pain responses.
Purpose of the Study:
- To investigate the role of DLC2 in pain modulation, particularly during inflammation.
- To characterize the physiological and molecular changes in DLC2-deficient mice.
Main Methods:
- Comparative analysis of wild-type (DLC2(+/+)) and DLC2-deficient (DLC2(-/-)) mice.
- Assessment of pain responses to thermal and chemical stimuli (formalin, acetic acid).
- Measurement of nerve conduction velocity and analysis of RhoA and ERK1/2 activity in the spinal cord.
Main Results:
- DLC2(-/-) mice exhibited hyperalgesia to thermal and inflammatory stimuli.
- Sensory nerve conduction velocity was increased in DLC2(-/-) mice, but motor nerve conduction was unaffected.
- Formalin injection led to increased spinal cord RhoA activity and elevated phosphorylated ERK1/2 levels in DLC2(-/-) mice.
Conclusions:
- DLC2 plays a significant role in modulating inflammatory pain by inhibiting RhoA and ERK1/2 activation.
- DLC2 deficiency results in exaggerated pain responses, mediated by RhoA and ERK1/2 pathways.
- DLC2(-/-) mice serve as a valuable model for studying inflammatory pain regulation.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Cell Polarization by Rho Proteins
GPCRs Regulate Adenylyl Cylase Activity
Two...
GPCR Desensitization
Activation and Inactivation of G Proteins
Analgesia and Pain Management